Boceprevir to PegIntron/Ribavirin Significantly Improves Sustained Virological
Response in Chronic Hepatitis C Patients
therapy using pegylated interferon
(Pegasys or PegIntron) plus ribavirin -- the current standard of care for
chronic hepatitis C virus (HCV) infection --
is associated with numerous side effects and about half the time does not produce
a sustained response. In an attempt to improve outcomes, researchers are studying
several oral agents that directly target various steps of the HCV lifecycle, an
approach known as "STAT-C."
the 44th Annual Meeting of the European Association for
the Study of the Liver (EASL 2009) last week in Copenhagen, investigators
reported final results from the Phase 2 HCV SPRINT-1 study, which evaluated the
safety and efficacy of Schering-Plough's investigational HCV
protease inhibitor boceprevir in various combinations with pegylated interferon
alfa-2b (PegIntron) plus ribavirin.
three-dimensional modelof boceprevir, a potential next generation Hep C
included 595 treatment-naive patients with genotype
1 chronic hepatitis C in the U.S., Canada and Europe. Overall, 16% of participants
were African-American, 7% had pre-existing liver
cirrhosis, 56% had HCV genotype 1a, and 89% had high HCV viral load (>
600,000 IU/mL), all factors associated with poor response to interferon-based
Boceprevir (800 mg 3 times daily) was evaluated as part of 3 treatment
Lead-in therapy with 1.5 mcg/kg once-weekly pegylated interferon plus 800-1400
mg daily weight-adjusted ribavirin for 4 weeks, followed by the addition of boceprevir
for 24 or 44 more weeks (for a total of 28 or 48 weeks of treatment);
Boceprevir in combination with the same doses of pegylated interferon plus ribavirin,
with all 3 drugs taken together for 28 or 48 weeks.
Boceprevir plus pegylated interferon plus low-dose 400-1000 mg daily weight-adjusted
ribavirin for 48 weeks (Part II).
Part I of the study, the boceprevir regimens were compared against the approved
standard of care control regimen of 1.5 mcg/kg once-weekly pegylated interferon
plus 800-1400 mg daily weight-adjusted ribavirin, without boceprevir, for 48 weeks.
In Part II, boceprevir plus pegylated interferon plus low-dose ribavirin
for 48 weeks was compared against boceprevir plus pegylated interferon plus full-dose
ribavirin for 48 weeks.
The rationale for the lead-in period was based
on the fact that both pegylated interferon alfa-2b and ribavirin reach steady-state
concentrations by week 4, therefore patients had boceprevir added after levels
of the other drugs were optimized and HCV viral load was reduced, according to
a Schering-Plough press release describing the study findings. This approach may
minimize the duration of "functional monotherapy" with the direct antiviral
agent, thereby potentially reducing the likelihood of developing resistance.
primary endpoint of the study was sustained
virological response (SVR), or continued undetectable HCV RNA after 24 weeks
of post-treatment follow-up.
Use of erythropoietin (EPO) to manage anemia
(defined as hemoglobin < 10 g/dL) during treatment was allowed at the discretion
of study investigators.
In the 28-week and 48-week boceprevir/pegylated interferon/ribavirin triple-therapy
arms with no lead-in period, SVR rates were 54% (58 of 107 patients) and 67% (69
of 103 patients), respectively.
In Part I of the study, response rates were improved in the arms with a 4-week
pegylated interferon/ribavirin lead-in period before starting boceprevir.
The 4-week pegylated interferon/ribavirin lead-in followed by 44 weeks of triple
combination therapy produced an SVR rate of 75% (77 of 103 patients), compared
with 38% in the standard of care control arm (39 of 104 patients) (P < 0.0001).
The SVR rate was 56% (58 of 103 patients) using the 4-week pegylated interferon/ribavirin
lead-in period followed by 24 weeks of triple combination therapy (P = 0.005 vs
standard of care).
In the lead-in arms, 64% of all patients achieved rapid virologic response (RVR),
defined as undetectable HCV RNA 4 weeks after adding boceprevir.
Among patients in the lead-in arms who achieved RVR, SVR rates were 94% using
the 48-week regimen and 82% using the 28-week regimen.
In Part II of the study, the SVR rate for the triple-combination regimen with
low-dose ribavirin was 36% (21 of 59 patients).
The low-dose ribavirin regimen was associated with an increased risk of viral
breakthrough during treatment and a higher relapse rate after the end of treatment,
resulting in a lower SVR rate.
Overall, triple-combination therapy was well tolerated.
In Part I of the study, 9%-19% of participants in the boceprevir arms discontinued
therapy due to adverse events, compared with 8% in the standard of care control
Fewer patients in the 28-week and 48-week lead-in arms discontinued treatment
due to viral breakthrough (4% and 5%, respectively, vs 7% and 12% with no lead-in).
The most common adverse events reported in the boceprevir arms were fatigue, anemia,
nausea, and headache.
The incidence of skin adverse events (rash or pruritus [itching]) was similar
in the boceprevir and standard of care arms.
About one-half of patients in the boceprevir arms and about one-third in the standard
therapy arm developed anemia during treatment.
39%-51% of patients in the boceprevir combination arms and 26% in the standard
of care control arm used EPO.
Participants who developed anemia had a greater likelihood of achieving SVR than
those without anemia.
28 and 48 week boceprevir regimens significantly increased SVR with very low relapse
rates in 48 week regimens," the investigators concluded. "However, low
dose ribavirin with PegIntron and boceprevir was associated with increased viral
breakthrough, relapse and lower efficacy. In contrast, pegylated interferon/ribavirin
lead-in prior to boceprevir substantially increased SVR and reduced viral breakthrough."
results are very exciting and provide important insights to help further define
response guided therapy using a pegylated interferon/ribavirin lead-in boceprevir
regimen with peginterferon and ribavirin backbone treatment," stated lead
investigator Paul Kwo, MD, in the Schering-Plough press release. "Building
on these results, the boceprevir Phase III clinical program individualizes treatment
based on response, utilizing RVR criteria at week 4 of boceprevir treatment to
determine overall duration of therapy. Based on the RVR rate seen in this Phase
II study, we are hopeful that the majority of patients can be treated with 28
weeks of therapy."
Patient enrollment has been completed in 2 ongoing
randomized, double-blind, placebo-controlled registration studies evaluating boceprevir
in combination with PegIntron and ribavirin: HCV SPRINT-2 in treatment-naive patients
and HCV RESPOND-2 in treatment-experienced relapsers and non-responders.
University School of Medicine, Indianapolis, IN; Alamo Medical Research, San Antonio,
TX; Mount Vernon Endoscopy Center, Alexandria, VA; Center for Liver Diseases,
University of Miami Miller School of Medicine, Miami, FL; Baylor College of Medicine,
Houston, TX; Indianapolis Gastroenterology Research Foundation, Indianapolis,
IN; Digestive Care/South Florida Center of Gastroenterology, Wellington, FL; Liver
Specialists of Texas, Houston, TX; Henry Ford Health Systems, Detroit, MI; Digestive
Disease Associates, Baltimore, MD; University of California-Davis Medical Center,
Sacramento, CA; Liver & Intestinal Research Center, Vancouver, BC, Canada;
Weill Cornell Medical College, New York, NY; Digestive Healthcare of Georgia,
Atlanta, GA; Schering-Plough Research Institute, Kenilworth, NJ.
Kwo, E Lawitz, J McCone, and others. HCV
SPRINT-1 Final Results: SVR 24 from a Phase 2 Study of Boceprevir Plus PegIntron
(Peginterferon Alfa-2b)/Ribavirin in Treatment-Naive Subjects with Genotype-1
Chronic Hepatitis C. 44th Annual Meeting of the European Association for the
Study of the Liver (EASL 2009). Copenhagen, Denmark. April 22-26, 2009. Abstract
Results of Boceprevir Phase II HCV Sprint-1 Study Showed Significantly Higher
SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis
C Patients. Press release. April 23, 2009.
2009 MAIN PAGE
2009 Conference Coverage
HIV and Hepatitis.com Highlights from EASL 2009
Conference on Retroviruses and Opportunistic Infections (CROI 2009)
by HIV and Hepatitis.com - February 8 - 11, 2009, Montreal
HIV and AIDS Treatment
News, Experimental News, FDA-approved News
of the 15th Conference on Retroviruses and Opportunistic Infections (CROI 2009)
- Coverage by HIV and Hepatitis.com, February 8 - 11, 2009, Montreal